Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction
Background: Clinical trials reported the benefit of empagliflozin when combined with standard treatment relative to cardiovascular death or heart failure (HF) hospitalization in patients with heart failure with reduced or preserved ejection fraction (HFrEF and HFpEF, respectively). We conducted a co...
Saved in:
Main Author: | Krittayaphong R. |
---|---|
Other Authors: | Mahidol University |
Format: | Article |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/85604 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction
by: Rungroj Krittayaphong, et al.
Published: (2022) -
Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
by: Rungroj Krittayaphong, et al.
Published: (2020) -
Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
by: Rungroj Krittayaphong, et al.
Published: (2020) -
Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction
by: Tay, Wan Ting, et al.
Published: (2023) -
Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction
by: Rungroj Krittayaphong, et al.
Published: (2020)